期刊
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
卷 6, 期 2, 页码 136-144出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-011-0084-z
关键词
Myelodysplastic syndromes (MDS); Iron overload; Transfusional hemosiderosis; Deferasirox; Deferoxamine; Iron chelation therapy; Clinical controversy; Classical dialogue; Labile plasma iron; Ferritin; Practice guidelines; T2*magnetic resonance imaging
Accumulation of excessive amounts of iron in vulnerable organs and tissues, together with elevated plasma and intracellular concentrations of reactive iron molecules, are likely to be harmful to some patients with myelodysplastic syndromes (MDS) who have received numerous red blood cell transfusions. But what is the real magnitude of risks related to iron overload in MDS, and how strong is the evidence that reducing total body iron and labile plasma iron through treatment with chelating drugs is beneficial to patients? Available data can be interpreted in different ways, and as a result, these topics continue to be areas of heated debate among physicians who care for patients with MDS. Using the traditional but rarely employed format of a classical dialogue, I explore here the potential dangers of iron overload and the risks and benefits of iron chelation therapy for patients with MDS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据